Mer, Arvind Singh http://orcid.org/0000-0001-8510-7963
Heath, Emily M.
Madani Tonekaboni, Seyed Ali
Dogan-Artun, Nergiz
Nair, Sisira Kadambat
Murison, Alex
Garcia-Prat, Laura
Shlush, Liran http://orcid.org/0000-0002-3700-270X
Hurren, Rose
Voisin, Veronique
Bader, Gary D. http://orcid.org/0000-0003-0185-8861
Nislow, Corey http://orcid.org/0000-0002-4016-8874
Rantalainen, Mattias
Lehmann, Soren
Gower, Mark
Guidos, Cynthia J. http://orcid.org/0000-0002-7674-2612
Lupien, Mathieu
Dick, John E. http://orcid.org/0000-0002-9527-8317
Minden, Mark D.
Schimmer, Aaron D. http://orcid.org/0000-0003-4023-3899
Haibe-Kains, Benjamin http://orcid.org/0000-0002-7684-0079
Funding for this research was provided by:
Princess Margaret Cancer Foundation
Ontario Institute for Cancer Research
Article History
Received: 13 July 2020
Accepted: 15 January 2021
First Online: 16 February 2021
Competing interests
: A.D.S. has received research funding from Takeda Pharmaceuticals and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. A.D.S. holds stock in Abbvie. A.D.S. is an inventor on patent applications claiming the use of DNTs for the treatment of AML. All other authors declare no competing interests.